PRA Health Sciences chosen BARDA exclusive Clinical Studies Network member

 KUALA LUMPUR, Oct 7 -- Global contract research organisation, PRA Health Sciences Inc has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to be a member of its updated Clinical Studies Network (CSN).

Under a Clinical Trial Planning and Execution (CTPE) contract award, PRA will serve as a valued partner providing clinical research services to develop medical countermeasures (MCMs) that protect health and save lives in public health emergencies.

“This programme represents important research that is necessary to protect and facilitate public health,” said PRA Health Sciences Senior Vice-President, Project Delivery and Biometrics, Michael Massaro.

BARDA aids in securing the nation from chemical, biological, radiological and nuclear threats, as well as pandemic influenza and emerging infectious diseases, according to a statement.

BARDA supports the advanced research, development and manufacturing of MCMs including vaccines, drugs and diagnostics.

It will leverage the CSN to advance the development of MCMs by conducting rigorous Phase I-IV clinical trials that assess the safety and efficacy of drugs, devices and biological products.

BARDA recently reconfigured the CSN contract to include the Clinical Trial Planning and Execution contract as a multi-award Indefinite Delivery/Indefinite Quantity contract over a five-year period.

During the term of their contract, PRA and other CSN CTPE members can submit additional proposals for new work within the project’s scope.

-- BERNAMA